LOUISVILLE, Ky., April 10, 2024 (GLOBE NEWSWIRE) -- BrightSpring Health Services ("BrightSpring" or "BrightSpring Health Services") (NASDAQ: BTSG) announced today that its company Onco360, a leading independent oncology pharmacy, was selected as a national pharmacy partner by Alexion Pharmaceuticals for a first-in-class, oral, Factor D inhibitor, Voydeya (Danicopan) to treat patients with a rare, life-threatening disease of the blood called paroxysmal nocturnal hemoglobinuria (PNH) who are experiencing extravascular hemolysis (EVH).
Voydeya is FDA-approved as add-on therapy to Ultomiris (Ravulizumab) or Soliris (Eculizumab) for patients living with PNH that experience continued anemia, or EVH. This innovative drug will complement current treatment regimens and help regulate the immune system, providing control and preventing the destruction of healthy blood cells.
"While PNH is only curable via bone marrow transplantation, this innovative drug from Alexion is a significant advancement in the treatment of PNH with EVH and will help improve the lives of those impacted by this disease," said BrightSpring's President and CEO, Jon Rousseau. "We are extremely proud of Onco360 for being selected as the preferred pharmacy for Voydeya as it shows the company's commitment to supporting cutting-edge treatment options the best possible way for patients living with cancer and complex diseases. We commend their leadership in partnering with biopharmaceutical leaders to continually innovate the proven standard-of-care."
"Onco360 is grateful and honored to partner with Alexion Pharmaceuticals to treat and support patients living with PNH with EVH and improve their quality of life," said Benito Fernandez, Chief Commercial Officer at Onco360. "This is another highly specialized, first-in-class drug that will complement current treatment regimens, and we're proud to be a trusted pharmacy and implement leading clinical and service practices for this drug and patients."
Onco360operates with the mission to improve the lives of patients battling cancer and living with other challenging and rare diseases. The pharmacy has robust access to limited distribution oncology medications and offers personalized services such as financial assistance sourcing, insurance benefit verification, expert clinical counseling, physician, patient and family education and support, rapid and accurate order processing and drug fulfillment, real-time digital and data support, Hub services, and 24/7 patient support.